Cross-Sector entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Bundibugyo ebolavirus, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Dr. Adelard Lufongola, all published on July 25, 2026.
1 verified story tracked
Last mentioned: Jul 25, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Bundibugyo ebolavirus, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Dr. Adelard Lufongola, all published on July 25, 2026. Each carries 4 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Adelard Lufongola. Shared-story counts are live from our verified record — not editorial picks.
The fastest-growing Ebola outbreak in history is driven by the Bundibugyo virus, which lacks any approved vaccine or therapy. With over 2,100 cases and 864 deaths, biopharma companies face a pressing unmet need and a potential market for rapid filovirus countermeasure development.
Source: wral.com · breitbart.com
